1. Home
  2. CNX vs BLTE Comparison

CNX vs BLTE Comparison

Compare CNX & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CNX Resources Corporation

CNX

CNX Resources Corporation

HOLD

Current Price

$38.29

Market Cap

5.6B

Sector

Energy

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

N/A

Current Price

$155.01

Market Cap

6.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNX
BLTE
Founded
1860
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.6B
IPO Year
1998
2021

Fundamental Metrics

Financial Performance
Metric
CNX
BLTE
Price
$38.29
$155.01
Analyst Decision
Sell
Strong Buy
Analyst Count
7
7
Target Price
$35.71
$198.00
AVG Volume (30 Days)
1.7M
98.2K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
763.33
N/A
EPS
2.18
N/A
Revenue
$2,239,134,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$11.14
$492.11
P/E Ratio
$17.52
N/A
Revenue Growth
76.76
N/A
52 Week Low
$27.72
$56.68
52 Week High
$43.62
$200.00

Technical Indicators

Market Signals
Indicator
CNX
BLTE
Relative Strength Index (RSI) 42.67 40.61
Support Level $37.42 $148.06
Resistance Level $38.28 $161.28
Average True Range (ATR) 1.01 6.20
MACD -0.01 -1.18
Stochastic Oscillator 21.28 3.36

Price Performance

Historical Comparison
CNX
BLTE

About CNX CNX Resources Corporation

CNX Resources Corp is an independent natural gas development, production, midstream and technology company centered in the Appalachian Basin. It is focused on unconventional shale formations, prominently the Marcellus Shale and Utica Shale, in Pennsylvania, Ohio and West Virginia. Additionally, the company operates and develops Coalbed Methane (CBM) properties in Virginia. the company has two reportable segments: Shale and Coalbed Methane. The majority of the company's revenue is derived from the Shale segment.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: